Dana Ishay-Ronen

Dr. Dana Ishay-Ronen

Oncology Institute of the Sheba Medical Center Tel Hashomer, Ramat Gan, Israel
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Cancer Cell
Verified
Journal Article
Closed access
Dana Ishay-RonenDana Ishay-Ronen
Dana Ishay-Ronen
MDMaren Diepenbruck
Maren Diepenbruck
RKRavi Kiran Reddy Kalathur
Ravi Kiran Reddy Kalathur
NSNami Sugiyama
Nami Sugiyama
STStefanie Tiede
Stefanie Tiede
GCGerhard Christofori
Gerhard Christofori

9 November 2022 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
JMJonathan M. Matthews
Jonathan M. Matthews
BSBrooke Schuster
Brooke Schuster
SKSara Saheb Kashaf
Sara Saheb Kashaf
PLPing Liu
Ping Liu
RBRakefet Ben-Yishay
Rakefet Ben-Yishay
STSavas Tay
Savas Tay
Organoids have immense potential as ex vivo disease models for drug discovery and personalized drug screening. Dynamic changes in individual organoid morphology, number, and size can indicate important drug responses. However, these metrics are difficult and labor-intensive to obtain for high-throughput image datasets. Here, we present OrganoID, a robust image analysis platform that automatically recognizes, labels, and tracks single organoids, pixel-by-pixel, in brightfield and phase-contrast microscopy experiments. The platform was trained on images of pancreatic cancer organoids and validated on separate images of pancreatic, lung, colon, and adenoid cystic carcinoma organoids, which showed excellent agreement with manual measurements of organoid count (95%) and size (97%) without any parameter adjustments. Single-organoid tracking accuracy remained above 89% over a four-day time-lapse microscopy study. Automated single-organoid morphology analysis of a chemotherapy dose-response experiment identified strong dose effect sizes on organoid circularity, solidity, and eccentricity. OrganoID enables straightforward, detailed, and accurate image analysis to accelerate the use of organoids in high-throughput, data-intensive biomedical applications.

22 July 2025 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ETErik Walter Thompson
Erik Walter Thompson
ARAndrew David Redfern
Andrew David Redfern
SBSimone Brabletz
Simone Brabletz
GBGeert Berx
Geert Berx
VAVeenoo Agarwal
Veenoo Agarwal
TBThomas Brabletz
Thomas Brabletz

1 November 2019 in Cancer Research
Verified
Journal Article
Closed access
Dana Ishay-RonenDana Ishay-Ronen
Dana Ishay-Ronen
GCGerhard Christofori
Gerhard Christofori
Cancer is a systemic heterogeneous disease that can undergo several rounds of latency and activation. Malignant tumors evolve through dynamic responses to microenvironmental signals and development of resistance following therapeutic interventions. Cancer cell adaptation is required for cell survival during metastatic dissemination and outgrowth. Epithelial–mesenchymal transition (EMT) plays a major role in facilitating cell plasticity in cancer and allows cancer cells to escape chemotherapies and targeted therapies through dedifferentiation and signaling adaptation processes. In our recent study, we showed that breast cancer cells that have undergone EMT can be terminally differentiated into adipocytes using the PPARγ agonist rosiglitazone combined with the MEK inhibitor trametinib. The conversion of invasive cancer cells into adipocytes repressed primary tumor invasion and metastasis formation in mouse models of breast cancer. The transdifferentiated cancer cell–derived adipocytes were growth-arrested and lost their cellular plasticity. These results indicate the high potential of utilizing the increased cell plasticity inherent to invasive cancer cells for transdifferentiation therapy.

11 August 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
NGNeta Bar-Hai Gochman
Neta Bar-Hai Gochman
Dana Ishay-RonenDana Ishay-Ronen
Dana Ishay-Ronen
Cancer is a systemic heterogeneous disease that can undergo several rounds of latency and activation. Tumor progression evolves by increasing diversity, adaptation to signals from the microenvironment and escape mechanisms from therapy. These dynamic processes indicate necessity for cell plasticity. Epithelial-mesenchymal transition (EMT) plays a major role in facilitating cell plasticity in solid tumors by inducing dedifferentiation and cell type transitions. These two practices, plasticity and dedifferentiation enhance tumor heterogeneity creating a key challenge in cancer treatment. In this review we will explore cancer cell plasticity and elaborate treatment modalities that aspire to overcome such dynamic processes in solid tumors. We will further discuss the therapeutic potential of utilizing enhanced cell plasticity for differentiation therapy.

1 October 2017 in Stem Cell Reports
Verified
Journal Article
Open access
GNGretel Nusspaumer
Gretel Nusspaumer
SJSumit Jaiswal
Sumit Jaiswal
ABAndrea Barbero
Andrea Barbero
RRRobert Reinhardt
Robert Reinhardt
Dana Ishay-RonenDana Ishay-Ronen
Dana Ishay-Ronen
RZRolf Zeller
Rolf Zeller
Bone-derived mesenchymal stromal cells (MSCs) differentiate into multiple lineages including chondro- and osteogenic fates and function in establishing the hematopoietic compartment of the bone marrow. Here, we analyze the emergence of different MSC types during mouse limb and long bone development. In particular, PDGFRαposSCA-1pos (PαS) cells and mouse skeletal stem cells (mSSCs) are detected within the PDGFRαposCD51pos (PαCD51) mesenchymal progenitors, which are the most abundant progenitors in early limb buds and developing long bones until birth. Long-bone-derived PαS cells and mSSCs are most prevalent in newborn mice, and molecular analysis shows that they constitute distinct progenitor populations from the earliest stages onward. Differential expression of CD90 and CD73 identifies four PαS subpopulations that display distinct chondro- and osteogenic differentiation potentials. Finally, we show that cartilage constructs generated from CD90pos PαS cells are remodeled into bone organoids encompassing functional endothelial and hematopoietic compartments, which makes these cells suited for bone tissue engineering.